Clinical Trial Update: A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. [Phase 3]

View source ↗

Summary

A Phase 3 trial compared ALIMTA (pemetrexed) plus GEMZAR (gemcitabine) versus GEMZAR alone in unresectable or metastatic pancreatic cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Gemzar (gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Pancreatic Neoplasms, Metastases, Neoplasm | Phase 3 | Status: COMPLETED